arrowhead läuft - zu recht

https://finance.yahoo.com/news/...eives-fda-fast-track-113000927.html  

über 60 offeneStellen
https://arrowheadpharma.com/careers/  

https://www.facebook.com/VogelBrosBuilding/videos/...755263706125643/  

Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK

Mon, April 3, 2023
https://finance.yahoo.com/news/...announces-30-million-113000672.html  

First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead

Tue, April 4, 2023
https://finance.yahoo.com/news/...ient-treated-alpha-1-113000710.html  

Arrowhead: A Compelling Investment In RNAi Therapeutics With Significant Upside Potential
Apr. 11, 2023 7:12 AM ETArrowhead Pharmaceuticals, Inc. (ARWR)
https://seekingalpha.com/article/...&utm_source=twitter_automated  

Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
Apr 12, 2023
https://ir.arrowheadpharma.com/news-releases/...ine-rnai-therapeutics
- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs

PASADENA, Calif.--(BUSINESS WIRE)--Apr. 12, 2023-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiMTM) platform to a total of 20 clinical stage or marketed products in the year 2025.

Arrowhead also announced that company has expanded its TRiMTM platform to include an optimized intrathecal administration for central nervous system (CNS) delivery with good distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform, ARO-SOD1, is on track for a clinical trial application (CTA) filing in the third quarter of 2023 to begin clinical studies.

ARO-SOD1 is designed to reduce expression of superoxide dismutase 1 (SOD1) in the CNS as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 was highly active against its target with a long duration of effect in multiple preclinical models suggesting that it may be administered quarterly or less frequently. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates.  

Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results

Tue, April 18, 2023
https://finance.yahoo.com/news/...-webcast-fiscal-2023-113000538.html
PASADENA, Calif., April 18, 2023--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023.  

https://finance.yahoo.com/news/...etary-pulmonary-trim-113000802.html  

Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
May 2, 2023
https://ir.arrowheadpharma.com/news-releases/...l-2023-second-quarter  

ein Forum auf das ich gestossen bin. Hier wird alles über Arrowhead gepostet.
https://discord.com/channels/855125100146589706/857396602757971988  

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Business Wire
Tue, May 16, 2023
https://finance.yahoo.com/news/...tes-enrollment-phase-113000408.html
 

Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
May 23, 2023
https://ir.arrowheadpharma.com/news-releases/...phase-2-gateway-study  

von Breeze:MS BUYSIDE ADDED 203K SHARES LAST Q. They are not being cautious. They are lying. Follow the money.
Pfizer spent $250M upfront for the Ionis version of ANG3, much earlier in its development than ARO-ANG3 is now. And it didn't work. ARO-ANG3 works. It is worth WAY more than that. Not hard to figure out.
https://discord.com/channels/855125100146589706/857399412463763457  

Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
Jun 1, 2023

1  New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95%

2 Adipose Delivery Platform Achieved Single Dose Target Gene Silencing of Greater than 90% with Six Months of Duration in Non-human Primates

3 Improved Hepatic Dimer Platform Achieves Equivalent or Better Knockdown of Two Target Genes with Longer Duration than Monomer Mixture in Non-human Primates

4 TRiM Platform Now has Potential to Address Multiple Cell Types Including Liver, Solid Tumors, Lung, Central Nervous System, Skeletal Muscle, and Adipose
https://ir.arrowheadpharma.com/news-releases/...ing-its-pipeline-rnai  

https://ir.arrowheadpharma.com/static-files/...4eff-8be7-c18bb3e1c5cc  

https://www.facebook.com/100059135780881/videos/.../?__so__=permalink  

TipRanks
Jun. 6, 2023, 04:25 AM

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $90.00. The company’s shares closed yesterday at $35.00.
https://markets.businessinsider.com/news/stocks/...ls-arwr-1032372406  

Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
Jun 6, 2023 at 7:30 AM EDT
PDF Version

PASADENA, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Jefferies Global Healthcare Conference – June 8, 2023
Type: Fireside chat presentation

Goldman Sachs 44th Annual Global Healthcare Conference – June 12, 2023
Type: Fireside chat presentation

European Association for the Study of the Liver (EASL) Congress 2023 – June 24, 2023
Type: Oral presentation
Title: Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study
Webcast links and presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
https://ir.arrowheadpharma.com/news-releases/...te-upcoming-june-2023  

noch ein neues Labor?
https://www.youtube.com/watch?v=Fs8c4yB-Vug
Check out the progress on this 150,000+ square-foot research & development facility. This ongoing development is the future site of a 55-acre technology and life science campus in Scripps Ranch  

Arrowhead: Biotech Innovation On Display
Jun. 06, 2023
https://seekingalpha.com/article/..._alpha&utm_term=31708802.1762  

Goldman Sachs Raises S&P 500 Price Target By 12.5%; Here Are 2 High-Upside Stocks To Play The Bounce
https://biz.crast.net/...are-2-high-upside-stocks-to-play-the-bounce/  

 

Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
Jun 24, 2023
https://ir.arrowheadpharma.com/news-releases/...phase-2-sequoia-study  

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
Jun 27, 2023
https://ir.arrowheadpharma.com/news-releases/...ry-clearance-initiate